收稿日期: 2023-08-09
网络出版日期: 2024-03-26
基金资助
国家自然科学基金项目(81773221);苏州市姑苏卫生人才科研项目(GSWS2021016);苏州市科技计划项目(SS201857)
The value of urine protein kinase Y⁃linked gene promoter site methylation in early diagnosis of prostate cancer
Received date: 2023-08-09
Online published: 2024-03-26
目的 探讨尿液蛋白激酶（PRKY）基因启动子位点甲基化在前列腺癌（PCa）早期诊断中的临床价值。 方法 收集50例疑似PCa患者的尿液，提取DNA后，通过定量甲基化特异性PCR（qMSP）法检测PRKY基因启动子位点cg05163709、cg08045599及cg05618150甲基化水平，同时将患者分为良性前列腺增生（BPH）组和PCa组，并分析两组患者临床指标差异以及两组患者尿液中的PRKY基因启动子位点甲基化状态。建立受试者工作特征曲线（ROC），计算曲线下面积（AUC），分析其在PCa中的诊断价值，并联合临床指标进行联合诊断。 结果 PCa患者尿液标本中cg05163709和cg05618150甲基化率明显高于BPH患者，其中cg05163709甲基化诊断PCa的AUC为0.762，敏感度为86.70%。与前列腺特异性抗原（tPSA）等临床指标相比，PRKY甲基化在PCa早期筛查中表现更好。cg05618150甲基化与前列腺特异抗原密度（PSAD）联合诊断的AUC为0.787，敏感度为86.70%；cg05163709甲基化与PSAD联合诊断PCa的AUC为0.855，特异度为95.00%。 结论 尿液PRKY基因启动子cg05163709和cg05618150位点甲基化在诊断PCa上具有较高的敏感度和特异度，有望成为PCa早期诊断的生物标志物。
刘伟峰 , 戴政 , 周毅彬 , 封凯文 , 魏恺 , 孙古乐 , 阳东荣 , 朱进 . 尿液蛋白激酶Y基因启动子位点甲基化在前列腺癌早期诊断中的价值[J]. 实用医学杂志, 2024 , 40(5) : 688 -694 . DOI: 10.3969/j.issn.1006-5725.2024.05.017
Objective To explore the clinical value of methylation at promoter sites of urine protein kinase Y-linked （PRKY） gene in the early diagnosis of prostate cancer（PCa）. Methods Urine samples were collected from 50 suspected PCa patients. After extracting DNA， the methylation levels of the PRKY gene promoter sites cg05163709， cg08045599， and cg05618150 were detected using quantitative methylation-specific PCR （qMSP）. Simultaneously， the patients were divided into the benign prostatic hyperplasia （BPH） group and the PCa group. The differences in clinical indicators between the two groups were analyzed， as well as the methylation status of the PRKY gene promoter sites in the urine of the two groups of patients. The receiver operating characteristic （ROC） curve of PRKY promoter sites methylation was established， and the area under the curve （AUC） was calculated to analyze the diagnostic value of PRKY promoter sites methylation in PCa， and to perform combined diagnosis with clinical indicators. Results The methylation rates of cg05163709 and cg05618150 in urine specimens of PCa patients were significantly higher than those of BPH patients. The AUC for cg05163709 methylation in diagnosing PCa was 0.762， with a sensitivity of 86.70%. It showed better performance in early screening for PCa compared to total prostate specific antigen （tPSA）， percentage free prostate specific antigen（f/tPSA）and prostate specific antigen density （PSAD）index. We found that the AUC for cg05618150 methylation in conjunction with PSAD in diagnosing PCa was 0.787， with a sensitivity of 86.70%. The AUC of cg05163709 methylation and PSAD in the joint diagnosis of PCa was 0.855， and the specificity could reach 95.00%. Conclusion The methylation of urine PRKY gene promoter sites cg05163709 and cg05618150 shows high sensitivity and specificity in diagnosing PCa， making them promising biomarkers for early detection of PCa.
| 1 | CULP M B， SOERJOMATARAM I， EFSTATHIOU J A， et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates［J］. Eur Urol， 2020，77（1）：38-52. doi:10.1016/j.eururo.2019.08.005 |
| 2 | SIEGEL R L， MILLER K D， JEMAL A. Cancer statistics， 2020［J］. CA Cancer J Clin， 2020，70（1）：7-30. doi:10.3322/caac.21590 |
| 3 | 孔琪，王章桂. 晚期前列腺癌治疗进展［J］. 实用医学杂志，2021，37（3）：410-414. |
| 4 | TEO M Y， RATHKOPF D E， KANTOFF P. Treatment of Advanced Prostate Cancer ［J］. Annu Rev Med， 2019，70：479-499. doi:10.1146/annurev-med-051517-011947 |
| 5 | KEARNS J T， LIN D W. Improving the Specificity of PSA Screening with Serum and Urine Markers［J］. Curr Urol Rep， 2018，19（10）：80. doi:10.1007/s11934-018-0828-6 |
| 6 | ESKRA J N， RABIZADEH D， PAVLOVICH C P， et al. Approaches to urinary detection of prostate cancer［J］. Prostate Cancer Prostatic Dis， 2019，22（3）：362-381. doi:10.1038/s41391-019-0127-4 |
| 7 | WILLIAMS I S， MCVEY A， PERERA S， et al. Modern paradigms for prostate cancer detection and management［J］. Med J Aust， 2022，217（8）：424-433. doi:10.5694/mja2.51722 |
| 8 | CACERES A， JENE A， ESKO T， et al. Extreme downregulation of chromosome Y and Alzheimer's disease in men［J］. Neurobiol Aging， 2020，90：150.e1-150.e4. doi:10.1016/j.neurobiolaging.2020.02.003 |
| 9 | BURKI T K. Association between extreme down-regulation of chromosome Y and cancer risk［J］. Lancet Oncol， 2020，21（2）：e72. doi:10.1016/s1470-2045(20)30030-9 |
| 10 | CáCERES A， JENE A， ESKO T， et al. Extreme Downregulation of Chromosome Y and Cancer Risk in Men［J］. J Natl Cancer Inst，2020，112（9）：913-920. doi:10.1093/jnci/djz232 |
| 11 | DASARI V K， GOHARDERAKHSHAN R Z， PERINCHERY G， et al. Expression analysis of Y chromosome genes in human prostate cancer［J］. J Urol， 2001，165（4）：1335-1341. doi:10.1016/s0022-5347(01)69895-1 |
| 12 | NISHIYAMA A， NAKANISHI M. Navigating the DNA methylation landscape of cancer［J］. Trends Genet， 2021，37（11）：1012-1027. doi:10.1016/j.tig.2021.05.002 |
| 13 | ROY D， TIIRIKAINEN M. Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer［J］. Trends Cancer，2020，6（2）：78-81. doi:10.1016/j.trecan.2019.12.006 |
| 14 | JIA J， SHI Y， CHEN L， et al. Decrease in Lymphoid Specific Helicase and 5-hydroxymethylcytosine Is Associated with Metastasis and Genome Instability［J］. Theranostics， 2017，7（16）：3920-3932. doi:10.7150/thno.21389 |
| 15 | SUGIURA M， SATO H， KANESAKA M， et al. Epigenetic modifications in prostate cancer［J］. Int J Urol， 2021，28（2）：140-149. doi:10.1111/iju.14406 |
| 16 | HAFFNER M C， ZWART W， ROUDIER M P， et al. Genomic and phenotypic heterogeneity in prostate cancer［J］. Nat Rev Urol， 2021，18（2）：79-92. doi:10.1038/s41585-020-00400-w |
| 17 | CONST?NCIO V， NUNES S P， HENRIQUE R， et al. DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types［J］. Cells， 2020，9（3）：624. doi:10.3390/cells9030624 |
| 18 | ZHAO F， OLKHOV-MITSEL E， KAMDAR S， et al. A urine-based DNA methylation assay， ProCUrE， to identify clinically significant prostate cancer［J］. Clin Epigenetics， 2018，10（1）： 147. doi:10.1186/s13148-018-0575-z |
| 19 | PAZIEWSKA A， DABROWSKA M， GORYCA K， et al. DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy［J］. Br J Cancer， 2014，111（4）：781-789. doi:10.1038/bjc.2014.337 |
| 20 | HOQUE M O， TOPALOGLU O， BEGUM S， et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects［J］. J Clin Oncol， 2005，23（27）：6569-6575. doi:10.1200/jco.2005.07.009 |
| 21 | 李爱群，于静，李晓鲲，等. RASSF1A与GSTP1基因甲基化检测对前列腺癌诊断价值的研究［J］. 中华肿瘤防治杂志，2017，24（17）：1220-1222. |
| 22 | CUI J， LI G， YIN J， et al. GSTP1 and cancer： Expression， methylation， polymorphisms and signaling （Review）［J］. Int J Oncol，2020，56（4）：867-878. |
| 23 | REN M， WANG C， SHENG D， et al. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis［J］. Ann Diagn Pathol，2 017，27：57-61. doi:10.1016/j.anndiagpath.2017.01.007 |
| 24 | EADS C A， DANENBERG K D， KAWAKAMI K， et al. MethyLight： a high-throughput assay to measure DNA methylation［J］. Nucleic Acids Res， 2000，28（8）：E32. doi:10.1093/nar/28.8.e32 |
| 25 | CHIU S T， CHENG Y T， PU Y S， et al. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection［J］. Front Oncol， 2021，11：772182. doi:10.3389/fonc.2021.772182 |
| 26 | VAN POPPEL H， ALBREHT T， BASU P， et al. Serum PSA-based early detection of prostate cancer in Europe and globally： past， present and future［J］. Nat Rev Urol， 2022，19（9）：562-572. doi:10.1038/s41585-022-00638-6 |
/
| 〈 |
|
〉 |